Saladax Biomedical specializes in the development and manufacturing of therapeutic drug monitoring (TDM) assays that are crucial for optimizing medication dosages for patients undergoing treatment for psychiatric and oncological conditions. Their flagship product, the 5-Fluorouracil (My5-FU) Assay, has recently received approval from Health Canada, highlighting the company's commitment to ensuring that patients receive the most effective and safe doses of chemotherapy. This assay is designed to monitor the levels of 5-Fluorouracil, a vital chemotherapy drug, thereby enabling healthcare providers to tailor treatments to individual patient needs.

In addition to their chemotherapy monitoring solutions, Saladax has introduced innovative testing methods such as a finger prick test for antipsychotic medications, which significantly reduces the time and complexity associated with traditional blood testing. This advancement not only streamlines the process of determining patient responses to medications like clozapine but also enhances patient care by facilitating quicker decision-making in treatment plans. Overall, Saladax Biomedical is at the forefront of improving therapeutic outcomes through precise drug monitoring technologies.

United States

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.

 

Saladax Biomedical

Company Details